Analysis of predictors of poor response or intolerance in patients with autoimmune hepatitis after treatment

Abstract

Abstract: Objective To evaluate the predictors of poor response or intolerance in autoimmune hepatitis (AIH) patients after treatment.Methods A total of 92 patients (26 males and 66 females) with AIH between January 2012 and July 2020 were reviewed. Normal ALT and AST were defined as post-treatment response (response group), ALT and AST maintained at 2 times the normal upper limit of (ULN) (treatment response was not good) or > 2 times ULN (treatment intolerance) was defined as no response after treatment (non-response group). M (P25, P75) denotes metrological data and Kruskal-Wallis H test comparison; (%) represents counting data and chi-square test comparison; Logistic regression analysis explores the influencing factors of poor response or intolerance in AIH patients.Results There were 55 cases in response group and 37 cases in non-response group. The age of diagnosis of AIH, the progression of AIH and liver cirrhosis were significantly different between the two groups (P<0.05), but there was no significant difference in sex, acute onset, AIH recurrence and autoimmune diseases between the two groups (P>0.05). There were significant differences in ALT, AST, anti-smooth muscle antibody (SMA) and anti-liver specific cytoplasmic antigen type I antibody (LC-1) between response group and non-response group (P<0.05), but there was no significant difference in TBIL, albumin, IgG, antinuclear antibody (ANA), anti-liver soluble antigen antibody (anti-SLA), anti-liver and kidney microsomal antibody (anti-LKM) and anti-mitochondrial antibody (AMA) (P>0.05). The age of diagnosis of AIH, the progression of AIH, liver cirrhosis, ALT, AST, AMA and LC-1 were included in Logistic regression analysis. The results showed that the age of diagnosis of AIH and liver cirrhosis were independent risk factors for poor response or intolerance in patients with AIH.Conclusion Younger age at the time of diagnosis of AIH and the occurrence of cirrhosis in the disease stage are the risk factors of poor response or intolerance in patients with AIH after treatment.

Key words: Autoimmune hepatitis, Liver cirrhosis, Smooth muscle antibodies

XIAO Xuan, QIAN Jin-li, LI Ting. Analysis of predictors of poor response or intolerance in patients with autoimmune hepatitis after treatment[J]. Chinese Hepatolgy, 2021, 26(8): 907-909.

References

[1] Lv T, Li M, Zeng N, et al. Systematic review and meta-analysis on the incidence and prevalence of autoimmune hepatitis in Asian, European, and American population. J Gastroenterol Hepatol, 2019, 34:1676-1684.
[2] Wu S, Yang Z, Zhou J, et al. Systematic review: diagnostic accuracy of non-invasive tests for staging liver fibrosis in autoimmune hepatitis. Hepatol Int, 2019, 13:91-101.
[3] Zhu B, You SL, Wan ZH, et al. Clinical characteristics and corticosteroid therapy in patients with autoimmune-hepatitis-induced liver failure. World J Gastroenterol, 2014, 20:7473-7479.
[4] Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology, 2010, 51:2193-2213.
[5] Selvarajah V, Montano-Loza AJ, Czaja AJ. Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. Aliment Pharmacol Ther, 2012, 36:691-707.
[6] Weiler-Normann C, Schramm C, Quaas A, et al. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol, 2013, 58:529-534.
[7] Ytting H, Larsen FS. Everolimus treatment for patients with autoimmune hepatitis and poor response to standard therapy and drug alternatives in use. Scand J Gastroenterol, 2015, 50:1025-1031.
[8] Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol,1999, 31:929-938.
[9] Feld JJ, Dinh H, Arenovich T, et al. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology, 2005, 42:53-62.
[10] Kirstein MM, Metzler F, Geiger E, et al. Prediction of short- and long-term outcome in patients with autoimmune hepatitis. Hepatology, 2015, 62:1524-1535.
[11] Yoshizawa K, Matsumoto A, Ichijo T, et al. Long-term outcome of Japanese patients with type 1 autoimmune hepatitis. Hepatology, 2012, 56:668-676.
[12] Puigvehí M, Broquetas T, Coll S, et al. Impact of anthropometric features on the applicability and accuracy of FibroScan. J Gastroenterol Hepatol, 2017, 32:1746-1753.
[13] Miyakawa H, Kawashima Y, Kitazawa E, et al. Low frequency of anti-SLA/LP autoantibody in Japanese adult patients with autoimmune liver diseases: analysis with recombinant antigen assay. J Autoimmun, 2003, 21:77-82.
[14] Couto CA, Bittencourt PL, Porta G, et al. Antismooth muscle and antiactin antibodies are indirect markers of histological and biochemical activity of autoimmune hepatitis. Hepatology, 2014, 59:592-600.
[15] Efe C, Ozaslan E, Wahlin S, et al. Antibodies to soluble liver antigen in patients with various liver diseases: a multicentre study. Liver Int, 2013, 33:190-196.